DRUG USAGE ANALYSIS AND HEALTH CARE RESOURCES CONSUMPTION IN PATIENTS WITH RHEUMATOID ARTHRITIS
Author(s)
Degli Esposti L1, Sangiorgi D1, Calandriello M2, Buda S1
1CliCon Srl, Ravenna, Italy, 2HE OR Unit - Bristol-Myers Squibb S.r.l., Rome, Italy
OBJECTIVES To prevent irreversible joint damage in rheumatoid arthritis (RA), biological drugs have been developed; when insufficient response is observed, the initial dosage could be increased (dose escalation). The aim of the study was to assess dose escalation among different therapeutic strategies and associated health care resources use. METHODS An observational retrospective cohort analysis based on 3 Local Health Units administrative databases was conducted. Patients who filled at least one prescription for biologic agents with a diagnosis of RA between 01/01/2009-31/12/2011 (enrolment period) were included. Patients were followed-up for 12 months and characterized on the basis of the previous 12 months. Dose escalation and cost of illness were calculated on naïve patients (patients with no prior prescriptions of the index biologic); dose escalation was defined as having ≥2 consecutive claims with an average weekly dose 130% greater than the initial average weekly dose. RESULTS
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PMS6
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Musculoskeletal Disorders